Inclusion Criteria:  Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study. Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests. Patients who underwent an NGS test with advanced HCC tissues Patients who are scheduled to receive atezolizumab with bevacizumab combination Patients with measurable lesions based on RECIST v1.1 ECOG performance status 0 or 1 Patients with a life expectancy of at least three months  Exclusion Criteria:  Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form Those who are assessed as not suitable for this study, at the discretion of the researcher